The Readout Loud

Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron

Share this episode
Anyone with this link can open it.
Share Link
Start at 0:00

This episode isn’t summarized yet

Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.

Show notes

Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights?

First, we discuss the FDA's decision to halt the use of two Covid-19 antibodies that don't work against Omicron — and the surprising backlash that ensued. Then, acting FDA commissioner Janet Woodcock joins us to dig into the agency's move and discuss the steps for regulation of Covid drugs. We also go over the latest news in the life sciences, including some bad news for Gilead Sciences and a rare victory for a small biotech company.

Couldn't load the audio. A blocker may be stopping the show's tracking links. Open the file